Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Ovid Therapeutics (OVID) is anticipated to report a Q3 2025 loss of $0.15 per share, representing a 25% year-over-year improvement, with revenues projected to double to $0.34 million. While the consensus EPS estimate has seen a 5.26% upward revision over the last 30 days, the company's Zacks Earnings ESP of -4.50% (indicating a more bearish 'Most Accurate Estimate') combined with a Zacks Rank of #3 suggests it is not a compelling candidate for an earnings beat, making a positive surprise difficult to predict.

Analysis

Ovid Therapeutics (OVID) is projected to report a Q3 2025 loss of $0.15 per share, representing a 25% year-over-year improvement, with revenues expected to double to $0.34 million. The consensus EPS estimate has seen a 5.26% upward revision over the past 30 days, indicating a collective reassessment by covering analysts. This suggests underlying operational progress despite the continued net loss.

Despite the upward revision, OVID's Zacks Earnings ESP is -4.50%, with the Most Accurate Estimate lower than the consensus, implying recent bearish analyst sentiment. Combined with a Zacks Rank of #3 (Hold), this makes a conclusive prediction of an earnings beat difficult, as negative ESP readings do not reliably predict a miss. Historically, OVID has beaten EPS estimates in two of the last four quarters, including a 62.50% surprise in the prior quarter.

The broader Medical - Biomedical and Genetics industry shows similar uncertainty, with Avidity Biosciences (RNA) also exhibiting a negative Earnings ESP and Zacks Rank #3, making its earnings beat difficult to predict. This sector-wide trend suggests caution regarding earnings surprises. Overall sentiment for OVID is neutral, reflecting the mixed signals from financial metrics and analyst models.

Key Decisions for Investors

• Prioritize management's forward guidance during the earnings call to assess business conditions and future outlook, as current earnings surprise indicators are inconclusive.
• Exercise caution regarding a significant positive earnings surprise, given OVID's negative Earnings ESP and Zacks Rank #3, which do not strongly predict an earnings beat.
• Consider OVID's performance in the context of broader industry trends, noting similar analytical uncertainties for peers within the Medical - Biomedical and Genetics sector.